Literature DB >> 21626410

Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein.

Uwe Walter1, Rike Witt, Alexander Wolters, Matthias Wittstock, Reiner Benecke.   

Abstract

In Parkinson's disease (PD), substantia nigra hyperechogenicity (SN-h) has been related to both, local iron accumulation and microglia activation. We analysed its relationship in PD patients with serum iron (n = 31) and C-reactive protein (CRP; n = 193). SN-h correlated with lower CRP and iron levels. Also, patients with a first-degree relative with PD had lower iron levels. Microglia activation, if reflected by SN-h, may be therefore unrelated to serum CRP. Findings support the idea that SN-h indicates inherited alteration of iron metabolism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21626410     DOI: 10.1007/s00702-011-0664-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  29 in total

1.  Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease.

Authors:  Alexei Korchounov; Hayo I Schipper; Irina S Preobrazhenskaya; Kirn R Kessler; Nikolay N Yakhno
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

2.  Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.

Authors:  Katherine J Schweitzer; Rüdiger Hilker; Uwe Walter; Lothar Burghaus; Daniela Berg
Journal:  Mov Disord       Date:  2006-01       Impact factor: 10.338

3.  MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis).

Authors:  V De Pablos; C Barcia; S Martínez; A Gomez; F Ros-Bernal; J Zamarro-Parra; J J Soria-Torrecillas; J Hernández; J J Ceron; M T Herrero
Journal:  Neurosci Lett       Date:  2009-07-26       Impact factor: 3.046

4.  Microglia activation is related to substantia nigra echogenicity.

Authors:  D Berg; J Godau; P Riederer; M Gerlach; T Arzberger
Journal:  J Neural Transm (Vienna)       Date:  2010-11-06       Impact factor: 3.575

Review 5.  Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.

Authors:  Li Qian; Patrick M Flood; Jau-Shyong Hong
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 7.  Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Authors:  Joshua J Gagne; Melinda C Power
Journal:  Neurology       Date:  2010-03-23       Impact factor: 9.910

8.  Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease.

Authors:  G Tórsdóttir; J Kristinsson; S Sveinbjörnsdóttir; J Snaedal; T Jóhannesson
Journal:  Pharmacol Toxicol       Date:  1999-11

9.  Anti-melanin antibodies are increased in sera in Parkinson's disease.

Authors:  K L Double; D B Rowe; F M Carew-Jones; M Hayes; D K Y Chan; J Blackie; A Corbett; R Joffe; V S Fung; J Morris; P Riederer; M Gerlach; G M Halliday
Journal:  Exp Neurol       Date:  2009-03-13       Impact factor: 5.330

10.  Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals.

Authors:  In-Uk Song; Joong-Seok Kim; Sung-Woo Chung; Kwang-Soo Lee
Journal:  Eur Neurol       Date:  2009-06-12       Impact factor: 1.710

View more
  4 in total

1.  Lenticular nucleus hyperechogenicity in Wilson's disease reflects local copper, but not iron accumulation.

Authors:  Uwe Walter; Marta Skowrońska; Tomasz Litwin; Grażyna Maria Szpak; Katarzyna Jabłonka-Salach; David Skoloudík; Ewa Bulska; Anna Członkowska
Journal:  J Neural Transm (Vienna)       Date:  2014-03-11       Impact factor: 3.575

2.  Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Cyrus P Zabetian; Shu-Ching Hu; Pinky Agarwal; Dora Yearout; Harvey Checkoway
Journal:  J Neural Transm (Vienna)       Date:  2016-06-27       Impact factor: 3.575

Review 3.  Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis.

Authors:  Dun-Hui Li; Ya-Chao He; Jun Liu; Sheng-Di Chen
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

4.  Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study.

Authors:  Irene Pichler; Fabiola Del Greco M; Martin Gögele; Christina M Lill; Lars Bertram; Chuong B Do; Nicholas Eriksson; Tatiana Foroud; Richard H Myers; Michael Nalls; Margaux F Keller; Beben Benyamin; John B Whitfield; Peter P Pramstaller; Andrew A Hicks; John R Thompson; Cosetta Minelli
Journal:  PLoS Med       Date:  2013-06-04       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.